Illumina, Inc.
ILMN
주식 순위
#604
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis... Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
주가
$268.04
마지막 동기화: 2026-10-20
시가총액
$40.47B
변동 (1일)
2.05%
변동 (1년)
170.86%
국가
US
거래 Illumina, Inc. (ILMN)
카테고리
Healthcare
Illumina, Inc. (ILMN)의 매출
Jun 2026 기준 매출 TTM: $4.49B
Illumina, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $4.49B입니다. 2024년에 회사는 $4.37B의 수익을 올렸으며 이는 2023년의 $4.50B 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Illumina, Inc.의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $4.49B | 3.48% |
| 2025 | $4.34B | -0.69% |
| 2024 | $4.37B | -2.93% |
| 2023 | $4.50B | -0.49% |
| 2022 | $4.53B | 39.73% |
| 2021 | $3.24B | -8.58% |
| 2019 | $3.54B | 6.30% |
| 2018 | $3.33B | 21.11% |
| 2017 | $2.75B | 14.74% |
| 2016 | $2.40B | 8.05% |
| 2015 | $2.22B | 19.25% |
| 2014 | $1.86B | 30.97% |
| 2013 | $1.42B | 23.74% |
| 2012 | $1.15B | 8.81% |
| 2011 | $1.06B | 16.93% |
| 2010 | $902.74M | 35.48% |
| 2009 | $666.32M | 16.24% |
| 2008 | $573.23M | 56.28% |
| 2007 | $366.80M | 98.71% |
| 2006 | $184.59M | 151.13% |
| 2005 | $73.50M | 45.31% |
| 2004 | $50.58M | 80.43% |
| 2003 | $28.04M | 179.23% |
| 2002 | $10.04M | 303.86% |
| 2001 | $2.49M | 89.90% |
| 2000 | $1.31M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $46.34B | 931.29% |
US
|
|
| $25.11B | 458.80% |
US
|
|
| $2.71B | -39.75% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 64.08% |
US
|
